Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD - The ABACOPD Study
BMC Pulmonary Medicine, ISSN: 1471-2466, Vol: 15, Issue: 1, Page: 5
2015
- 17Citations
- 72Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef5
- Captures72
- Readers72
- 72
- Mentions1
- News Mentions1
- 1
Most Recent News
Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD - The ABACOPD Study
Study protocol Gernot G Rohde , Armin Koch and Tobias Welte BMC Pulmonary Medicine 2015, 15 :5 doi:10.1186/1471-2466-15-5 Published: 27 January 2015 Abstract (provisional) Background
Article Description
Background: Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in hospitals and the community. Acute exacerbations of COPD (AE-COPD) often result in administration of antibiotics although more than half of exacerbations are associated with detection of respiratory viruses and potentially pathogenic bacteria can only be detected in 20-30% of cases. There is a paucity of placebo-controlled clinical trials and up to today no single study has been powered sufficiently to prove the efficacy of antibiotic treatment in AE-COPD. Most studies so far did not include current standards of care comprising administration of systemic corticosteroids. Methods/Design: A total of 980 patients with moderate acute exacerbations will be included in 22 German centers (hospitals and private practices). Patients will receive a standardized treatment for exacerbation including systemic corticosteroids, inhaled bronchodilators and supplementary oxygen if needed and will be randomized to additional treatment with placebo or antibiotic (oral sultamicillin) for five days. The primary endpoint is clinical failure defined by need for additional antibiotic treatment until day 30. Secondary endpoints will assure that management of AE-COPD without antibiotics does not result either in increased occurrence of relapse, new exacerbations, prolonged recovery, or unwanted long-term consequences. Discussion: ABACOPD will be the first sufficiently powered double-blind placebo-controlled study in the field to systematically assess the question whether antibiotics, known to increase antibiotic resistance, are really needed in a well-defined patient cohort receiving state-of-the art treatment in all other aspects.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84928813719&origin=inward; http://dx.doi.org/10.1186/1471-2466-15-5; http://www.ncbi.nlm.nih.gov/pubmed/25623589; https://clinicaltrials.gov/ct2/show/NCT01892488; https://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-15-5; https://dx.doi.org/10.1186/1471-2466-15-5; https://bmcpulmmed.biomedcentral.com/counter/pdf/10.1186/1471-2466-15-5; http://link.springer.com/article/10.1186/1471-2466-15-5/fulltext.html; https://link.springer.com/track/pdf/10.1186/1471-2466-15-5; https://link.springer.com/articles/10.1186/1471-2466-15-5; https://link.springer.com/article/10.1186/1471-2466-15-5; http://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-15-5; http://www.biomedcentral.com/1471-2466/15/5
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know